""

Bio-Rad Laboratories, Inc. reported its 2025 Q4 earnings, providing a comprehensive overview of the company's financial performance. The presentation outlined the company's revenue, which reached $732 million, a 7% increase from the same period in 2024. Net income for the quarter was $141 million, with diluted earnings per share of $4.83. The company's life science segment saw a 10% increase in revenue, driven by strong demand for its PCR and gene expression products. Bio-Rad's diagnostics segment also experienced growth, with a 5% increase in revenue. The company's CEO, Norman Schwartz, attributed the strong results to the company's focus on innovation and customer satisfaction. As a leading global supplier of life science and clinical diagnostic products, Bio-Rad's positive earnings report has significant implications for the biotechnology industry, indicating a strong demand for life science research and diagnostic tools. The company's solid financial performance positions it for continued growth and expansion in 2026.